Spark Therapeutics (Spark Therapeutics) Cash-to-Debt : 2.85 (As of Sep. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Spark Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2019 was 2.85.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Spark Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2019.

The historical rank and industry rank for Spark Therapeutics's Cash-to-Debt or its related term are showing as below:

ONCE's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.52
* Ranked among companies with meaningful Cash-to-Debt only.

Spark Therapeutics Cash-to-Debt Historical Data

The historical data trend for Spark Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Spark Therapeutics Cash-to-Debt Chart

Spark Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

194.08

424.97

8.91

Spark Therapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Cash-to-Debt	Get a 7-Day Free Trial															11.58	8.91	4.47	2.90	2.85

Competitive Comparison of Spark Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Spark Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spark Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spark Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Spark Therapeutics's Cash-to-Debt falls into.

Spark Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Spark Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	453.606	/	(4.822	+	46.09)
	=	8.91

Spark Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	389.912	/	(16.197	+	120.749)
	=	2.85

Spark Therapeutics (NAS:ONCE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Spark Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Spark Therapeutics (Spark Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104

Website

http://www.sparktx.com

Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.

Executives

Elliot Sigal	director
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster	officer: CHIEF FINANCIAL OFFICER	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga	officer: Chief Business Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth	director, officer: CHIEF SCIENTIFIC OFFICER	334 CR 692, BUFFALO GAP TX 79508
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd	10 percent owner	ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High	director, officer: See Remarks	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey	officer: Chief Operating Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio	officer: Chief Commercial Officer	225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju	10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025